Prosecution Insights
Last updated: April 19, 2026
Application No. 17/969,043

INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN

Non-Final OA §112
Filed
Oct 19, 2022
Examiner
OH, TAYLOR V
Art Unit
1625
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Morphic Therapeutic Inc.
OA Round
1 (Non-Final)
81%
Grant Probability
Favorable
1-2
OA Rounds
2y 5m
To Grant
96%
With Interview

Examiner Intelligence

Grants 81% — above average
81%
Career Allow Rate
1415 granted / 1742 resolved
+21.2% vs TC avg
Strong +15% interview lift
Without
With
+15.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
35 currently pending
Career history
1777
Total Applications
across all art units

Statute-Specific Performance

§101
0.4%
-39.6% vs TC avg
§103
33.6%
-6.4% vs TC avg
§102
19.5%
-20.5% vs TC avg
§112
37.3%
-2.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1742 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Non-Final Rejection The Status of Claims: Claims 1, 5,10-15,18-23, 26-27, 30 and 37-39 are pending. Claims 1, 5,10-15, 22-23, 26-27 are rejected. Claims 18-21, 30, 37-39 are objected. DETAILED ACTION 1. Claims 1, 5,10-15,18-23, 26-27,30 and 37-39 are under consideration in this Office Action. Priority 2. It is noted that this application is a continuation of 17718842 04/12/2022 (ABN )m which is a continuation of 17513361 10/28/2021(ABN), which is a continuation of 17271994 02/26/2021(ABN),is a 371 of PCT/US19/48737 08/29/2019 , which has a priority date of 62724400 08/29/2018. Drawings 3. None. IDS 4. The IDS filed on 3/31/23, 7/31/23, 8/25/23, 11/15/23, and 8/12/25 were reviewed by the examiner. Election/Restriction Applicant’s election of a single compound without traverse of Claims 1, 5,10-15,18-23, 26-27,30 and 37-39 on 8/12/2025 is acknowledged. The elected compound on page 142 of the application, PNG media_image1.png 187 389 media_image1.png Greyscale is allowable. Claim Objections Claims 18-21, 30, 37-39 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1, 5,10-15, 22-23, 26-27 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. In Claims 1 and 14, the phrase” R2 is substituted ,..bicyclic heterocyclyl “ is recited .This expression is vague and indefinite because in the absence of the specific moieties intended to effectuate modification by the “substitution” or attachment to the chemical core claimed, the term “substituted” renders the claims in which it appears indefinite in all occurrences wherein applicants fails to articulate by chemical name, structural formula or sufficiently distinct functional language, the particular moieties applicants regards as those which will facilitate substitution, requisite to identifying the composition of matter claimed. In claims 1, 13-14, the limitation “R2 is substituted or unsubstituted bicyclic heterocyclyl, wherein at least one ring atom of the bicyclic heterocyclyl is O” is recited. This expression can be vague and indefinite because the claim does not specify what other hetero atoms are present besides oxygen atom in the other ring atom of the bicyclic heterocyclyl group in the claims. The examiner recommends to put the specific hetero atom(s) for the bicyclic heterocyclyl group in the claims. The Close Prior Art The close prior art to the current invention is Morgans et al (WO2018/119087), which discloses a following compound: PNG media_image2.png 277 571 media_image2.png Greyscale . However, the claimed invention differs from the prior art in that the variable B of the claimed compound is-alkylene-(O)- and the variable R2 of the claimed compound is a substituted or unsubstituted bicyclic heterocyclyl. Therefore, it would have been unobvious over the claimed invention. Conclusion Claims 1, 5,10-15, 22-23, 26-27 are rejected. Claims 18-21, 30, 37-39 are objected. Any inquiry concerning this communication or earlier communications from the examiner should be directed to TAYLOR V OH whose telephone number is (571)272-0689. The examiner can normally be reached 8:00-5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at 571-272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /TAYLOR V OH/Primary Examiner, Art Unit 1625 1/02/2026
Read full office action

Prosecution Timeline

Oct 19, 2022
Application Filed
Jan 02, 2026
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599614
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND PROPHYLAXIS OF MICROBIAL INFECTIOUS DISEASES AND ASSOCIATED INFLAMMATORY DISORDERS AND FOR THE TREATMENT AND PROPHYLAXIS OF AGING AND ASSOCIATED DISEASES
2y 5m to grant Granted Apr 14, 2026
Patent 12600724
INDOLE ALKALOID AND PREPARATION METHOD AND USE THEREOF
2y 5m to grant Granted Apr 14, 2026
Patent 12594279
COMPOSITION FOR PREVENTING OR TREATING TNF-alpha-RELATED DISEASE, COMPRISING HYDROFLUMETHIAZIDE AS ACTIVE INGREDIENT
2y 5m to grant Granted Apr 07, 2026
Patent 12595240
PROCESS FOR THE PRODUCTION OF ETHYLENE OXIDE
2y 5m to grant Granted Apr 07, 2026
Patent 12582649
COMPOSITIONS AND METHODS FOR HAIR FOLLICLE REGENERATION
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
81%
Grant Probability
96%
With Interview (+15.3%)
2y 5m
Median Time to Grant
Low
PTA Risk
Based on 1742 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month